SE401827B - Sett att framstella 1-och3-substituerade 4-fenylpiperidiner - Google Patents

Sett att framstella 1-och3-substituerade 4-fenylpiperidiner

Info

Publication number
SE401827B
SE401827B SE7401101A SE7401101A SE401827B SE 401827 B SE401827 B SE 401827B SE 7401101 A SE7401101 A SE 7401101A SE 7401101 A SE7401101 A SE 7401101A SE 401827 B SE401827 B SE 401827B
Authority
SE
Sweden
Prior art keywords
phenylpiperidines
substituted
preparing
Prior art date
Application number
SE7401101A
Other languages
English (en)
Swedish (sv)
Inventor
J A Christensen
R F Squires
Original Assignee
Ferrosan As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9778288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE401827(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrosan As filed Critical Ferrosan As
Publication of SE401827B publication Critical patent/SE401827B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE7401101A 1973-01-30 1974-01-29 Sett att framstella 1-och3-substituerade 4-fenylpiperidiner SE401827B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB449673A GB1422263A (en) 1973-01-30 1973-01-30 4-phenyl-piperidine compounds

Publications (1)

Publication Number Publication Date
SE401827B true SE401827B (sv) 1978-05-29

Family

ID=9778288

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7401101A SE401827B (sv) 1973-01-30 1974-01-29 Sett att framstella 1-och3-substituerade 4-fenylpiperidiner

Country Status (20)

Country Link
US (2) US3912743A (de)
JP (2) JPS5946216B2 (de)
AT (1) AT333759B (de)
BE (1) BE810310A (de)
CA (1) CA1038390A (de)
CH (1) CH592059A5 (de)
DE (1) DE2404113C2 (de)
DK (1) DK149843C (de)
ES (2) ES422734A1 (de)
FI (1) FI57932C (de)
FR (1) FR2215233B1 (de)
GB (1) GB1422263A (de)
HK (1) HK13081A (de)
IE (1) IE38801B1 (de)
IT (1) IT1054157B (de)
LU (2) LU69264A1 (de)
NL (2) NL179187C (de)
NO (1) NO144568C (de)
PH (1) PH10383A (de)
SE (1) SE401827B (de)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800378A (en) * 1972-06-07 1974-04-02 Rca Corp Method of making a directly-heated cathode
US4442113A (en) * 1981-05-07 1984-04-10 A/S Ferrosan Long-term weight reduction of obese patients using femoxetine
US4485109A (en) * 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
DK149624C (da) * 1983-03-07 1987-02-02 Ferrosan As Fremgangsmaade til fremstilling af (+)-trans-3-((4-methoxyphenoxy)-methyl)-1-methyl-4-phenylpiperidin eller et farmaceutisk acceptabelt salt heraf ud fra en blanding af enantiomererne
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
US4593036A (en) * 1984-02-07 1986-06-03 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidine useful as 5-HT potentiator
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (de) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidinderivate mit gastro-intestinaler Wirkung
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223334B1 (de) * 1985-08-10 1991-07-10 Beecham Group Plc Verfahren zur Herstellung von Arylpiperidincarbinol
NO158038C (no) * 1985-10-21 1988-06-29 Standard Tel Kabelfab As Kabel.
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK588289D0 (da) * 1989-11-22 1989-11-22 Ferrosan As Ny heterocyklisk kemi
DK640289D0 (da) * 1989-12-18 1989-12-18 Ferrosan As Ny heterocyklisk kemi
IL98757A (en) * 1990-07-18 1997-01-10 Novo Nordisk As Piperidine derivatives their preparation and pharmaceutical compositions containing them
AU658155B2 (en) * 1990-11-24 1995-04-06 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, or anorexia
US5512584A (en) * 1991-04-16 1996-04-30 Basf Aktiengesellschaft 1,3,4-trisubstituted piperidine derivatives, the preparation and use thereof
DE4112353A1 (de) * 1991-04-16 1992-10-22 Basf Ag 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9305175D0 (en) * 1993-03-13 1993-04-28 Smithkline Beecham Plc Novel process
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
EP0639568A1 (de) * 1993-08-19 1995-02-22 Novo Nordisk A/S Piperinderivate, ihre Herstellung und ihre Verwendung zur Behandlung von neurodegenerativen Krankenheiten
US5446057A (en) * 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
ES2102295B1 (es) * 1994-03-18 1998-04-01 Ferrer Int Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
HUP9900318A3 (en) * 1995-05-17 2001-09-28 Novo Nordisk As Process for preparing 4-aryl-piperidine derivatives
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
AU6776196A (en) * 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response
NZ315677A (en) * 1995-09-07 2000-02-28 F 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
ES2121685B1 (es) * 1996-04-10 1999-09-16 Vita Invest Sa Procedimiento para la obtencion de (+)-trans-4(4-fluoro-fenil)-3-hidroximetil-1-metilpiperidina.
JP3446468B2 (ja) 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP0812827B1 (de) 1996-06-13 2009-09-02 Sumitomo Chemical Company, Limited Piperidin Derivative als Zwischenprodukte zur Herstellung von Paroxetine und Verfahren zu ihrer Herstellung
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
GB9623359D0 (en) * 1996-11-09 1997-01-08 Smithkline Beecham Plc Novel process
GB9700690D0 (en) * 1997-01-15 1997-03-05 Smithkline Beecham Plc Novel process
ES2329739T3 (es) * 1997-04-07 2009-11-30 Georgetown University Analogos de cocaina.
GB9710004D0 (en) 1997-05-17 1997-07-09 Knoll Ag Chemical process
AP9901698A0 (en) 1997-05-29 1999-12-31 Smithkline Beecham Corp Novel process.
CN1092654C (zh) * 1997-06-10 2002-10-16 斯索恩有限公司 4－苯基哌啶类化合物
EP1078925A1 (de) 1997-06-10 2001-02-28 Synthon B.V. 4-Phenylpiperidin-Derivate
CA2212451C (en) * 1997-08-07 2001-10-02 Brantford Chemicals Inc. Stereoselective and useful preparation of 3-substituted 4-aryl piperidine compounds
ES2137131B1 (es) * 1998-02-06 2000-09-16 Vita Invest Sa Derivado de piperidinona procedimiento de obtencion y procedimiento para su utilizacion.
ID27596A (id) * 1998-03-16 2001-04-12 Smithkline Beecham Plc Bentuk paroksetina kristal
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
EP1073652A1 (de) * 1998-04-09 2001-02-07 Smithkline Beecham Plc Paroxetin-maleat
GB9808896D0 (en) * 1998-04-25 1998-06-24 Smithkline Beecham Plc Novel compound
DE69910691T2 (de) 1998-06-29 2004-07-08 Sumika Fine Chemical Co. Ltd. L-Tartrate von Trans-(-)-4-(4-Fluorphenyl)-3-Hydroxymethyl-Piperidin Verbindungen und Verfahren zu ihrer Herstellung
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) * 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
EP1100796B1 (de) * 1998-08-07 2003-05-02 SmithKline Beecham plc Verfahren zur herstellung von einer nicht-kristallinen wasswerfreien form von paroxetin hydrochlorid
WO2000020390A1 (en) * 1998-10-07 2000-04-13 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
ATE255577T1 (de) * 1998-11-30 2003-12-15 Smithkline Beecham Plc Gemischte paroxetin-propan-2-olsolvate
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
JP2002533325A (ja) * 1998-12-22 2002-10-08 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド アリールピペリジンカルビノール中間体および誘導体の製造方法
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9915303D0 (en) * 1999-06-30 1999-09-01 Smithkline Beecham Plc Novel process
WO2001002393A1 (en) * 1999-07-01 2001-01-11 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
GB9915727D0 (en) * 1999-07-03 1999-09-08 Smithkline Beecham Plc Novel compound and process
GB9916187D0 (en) * 1999-07-09 1999-09-08 Smithkline Beecham Plc Novel process
GB9916392D0 (en) * 1999-07-13 1999-09-15 Smithkline Beecham Plc Novel process
IT1313702B1 (it) * 1999-08-02 2002-09-09 Chemi Spa Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
GB9920147D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel process
GB9923540D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9923539D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9924882D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel process
WO2001029002A1 (en) * 1999-10-20 2001-04-26 Smithkline Beecham Plc Process for the preparation of 4-(fluorophenyl)piperidine esters
GB9924855D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel processes
US6503927B1 (en) 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
AU2000246280A1 (en) * 2000-05-12 2001-11-20 Synthon B.V. Tosylate salts of 4-(p-fluorophenyl)-piperidine-3-carbinols
US6833458B2 (en) 2000-06-05 2004-12-21 Development Center For Biotechnology Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates
JP2004504319A (ja) * 2000-07-17 2004-02-12 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー ４−フェニルピペリジン誘導体の新規製造方法
GB0021145D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
GB0021147D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
AU2001211337A1 (en) * 2000-10-06 2002-04-15 Smithkline Beecham Plc Process for the preparation of aryl-piperidine carbinols and intermediates thereof
WO2002032870A1 (en) * 2000-10-20 2002-04-25 Smithkline Beecham P.L.C. Process of the preparation of 3-substituted-4-aryl piperidine compounds
JP2004520333A (ja) * 2001-01-04 2004-07-08 フエルレル インターナショナル，ソシエダッド アノニマ （±）−トランス−４−ｐ−フルオロフェニル−３−ヒドロキシメチル−１−メチルピペリジンの製造方法。
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6777554B2 (en) 2001-02-05 2004-08-17 Teva Pharmaceutical Industries Ltd. Preparation of N-methylparoxetine and related intermediate compounds
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
AU2002232017A1 (en) * 2001-02-24 2002-09-12 Spurcourt Limited Process of preparing paroxetine and intermediates for use therein
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
CA2457382A1 (en) * 2001-06-13 2002-12-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of paroxetine substantially free of alkoxy impurities
CA2456233A1 (en) * 2001-08-02 2003-03-13 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
CA2462903C (en) * 2001-10-12 2011-09-20 Serenix Pharmaceuticals, Llc Beta-lactamyl vasopressin v1a antagonists
IL161521A0 (en) * 2001-10-22 2004-09-27 Synthon Bv N-formyl derivatives of paroxetine
IL162666A0 (en) * 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
US6956121B2 (en) 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
US7138523B2 (en) * 2002-05-16 2006-11-21 Apotex Pharmachem Inc. Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters
KR100477048B1 (ko) * 2002-07-05 2005-03-17 임광민 피페리딘 화합물의 새로운 제조방법
AU2003277827A1 (en) * 2002-11-01 2004-05-25 Neurosearch A/S Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2004043921A1 (en) * 2002-11-11 2004-05-27 Natco Pharma Limited Novel process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines.
NZ543741A (en) 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
RU2320369C2 (ru) 2003-09-12 2008-03-27 Пфайзер Инк. Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина
NZ545836A (en) * 2003-09-17 2009-09-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
EP1737473A4 (de) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Lithium-kombinationen und relevante verwendungen
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
EP1868434A4 (de) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc Beta-lactamylalkansäuren zur behandlung von prämenstruellen störungen
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
EP1871358A1 (de) 2005-04-22 2008-01-02 Wyeth Benzofuranyl-alkanamin-derivate und deren verwendung als 5-ht2c-agonisten
GT200600164A (es) 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
EP1879875A1 (de) * 2005-04-22 2008-01-23 Wyeth Kristallformen von {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amin-hydrochlorid
US20060264637A1 (en) * 2005-05-16 2006-11-23 Thippannachar Vijayavitthal M Preparation of paroxetine hydrochloride hemihydrate
CA2614289A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
BRPI0613664B1 (pt) * 2005-07-19 2021-08-24 Azevan Pharmaceuticals, Inc Compostos antagonistas de beta-lactamil fenilalanina, cisteína e serina vasopressina, composição farmacêutica que compreende ditos compostos e usos terapêuticos dos mesmos
CA2616383C (en) * 2005-07-29 2015-06-09 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
EP1948646A2 (de) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Substituierte phenylpiperidine mit serotoninerger aktivität und verbesserten therapeutischen eigenschaften
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008036678A2 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008086483A2 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
AU2008299921B2 (en) * 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
EP2288345B1 (de) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psychopharmazeutika
EP2303859A4 (de) * 2008-06-20 2012-08-22 Metabolex Inc Aryl-gpr119-agonisten und verwendungen davon
AR074128A1 (es) 2008-11-14 2010-12-22 Theravance Inc Derivados de 4-[2-(2-fluorofenoximetil)fenil] piperidina, composiciones farmaceuticas que los contienen, metodo de preparacion, compuestos intermediarios de dicho proceso y uso de los mismos para el tratamiento de dolores neuropaticos, mal de alzheimer y otras enfermedades relacionadas con el snc.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP5909185B2 (ja) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩
EP2523945A1 (de) * 2010-01-11 2012-11-21 Theravance, Inc. 1-(2-phenoxymethylphenyl-)piperazinverbindungen als serotonin- und norepinephrin-wiederaufnahmehemmer
US8530663B2 (en) * 2010-03-22 2013-09-10 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
CA2802541A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US9376424B2 (en) 2010-07-01 2016-06-28 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
US20140010883A1 (en) 2011-03-17 2014-01-09 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
BR112014016197A8 (pt) 2012-01-31 2017-07-04 Eisai R&D Man Co Ltd derivado de paroxetina
CN116327950A (zh) 2014-03-28 2023-06-27 阿泽范药品公司 组合物用于治疗神经退行性疾病的神经精神症状的用途
JP2019527693A (ja) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
EP3681871A4 (de) 2017-09-15 2021-05-26 Azevan Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von hirnverletzungen
KR20220049526A (ko) 2019-07-19 2022-04-21 바이오엑셀 테라퓨틱스 인코포레이티드 비-진정성 덱스메데토미딘 치료 양생법
WO2023102477A1 (en) * 2021-12-02 2023-06-08 The Johns Hopkins University Peripherally and luminally-restricted inhibitors of the serotonin transporter as treatments for disorders of gastrointestinal motility
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2976291A (en) * 1961-03-21 Ethers of z
US3178438A (en) * 1963-02-06 1965-04-13 Sterling Drug Inc 2-benzyl-3-hydroxy and lower alkoxy piperidines

Also Published As

Publication number Publication date
PH10383A (en) 1977-03-02
BE810310A (fr) 1974-05-16
IT1054157B (it) 1981-11-10
JPS5946216B2 (ja) 1984-11-10
ATA69674A (de) 1976-04-15
FI57932C (fi) 1980-11-10
US4007196A (en) 1977-02-08
LU88398I2 (fr) 1994-05-04
IE38801B1 (en) 1978-06-07
NL930003I2 (nl) 1994-03-01
ES422734A1 (es) 1976-04-01
DK149843B (da) 1986-10-13
FR2215233B1 (de) 1977-01-28
FI57932B (fi) 1980-07-31
LU69264A1 (de) 1974-04-10
FR2215233A1 (de) 1974-08-23
CA1038390A (en) 1978-09-12
US3912743A (en) 1975-10-14
AT333759B (de) 1976-12-10
NO144568C (no) 1981-09-23
JPS58174363A (ja) 1983-10-13
CH592059A5 (de) 1977-10-14
GB1422263A (en) 1976-01-21
JPS49101385A (de) 1974-09-25
HK13081A (en) 1981-04-10
DK149843C (da) 1987-06-15
DE2404113A1 (de) 1974-08-08
IE38801L (en) 1974-07-30
ES8707224A3 (es) 1987-07-16
ES556013A0 (es) 1987-07-16
JPS5948826B2 (ja) 1984-11-29
NO144568B (no) 1981-06-15
NL179187C (nl) 1986-08-01
NO740272L (no) 1974-07-31
NL179187B (nl) 1986-03-03
DE2404113C2 (de) 1985-07-11
NL7401189A (de) 1974-08-01

Similar Documents

Publication Publication Date Title
SE401827B (sv) Sett att framstella 1-och3-substituerade 4-fenylpiperidiner
SE419981B (sv) Forfarande for framstellning av 1alfa-hydroxi-vitamin d-derivat
SE453667B (sv) Forfarande for framstellning av polyeterimider
SE7808959L (sv) Forfarande for framstellning av dylenoxid
BG21394A3 (bg) Метод за получаване на 1-арилокси-2-хидрокси-3- алкинил-аминопропани
SE7408486L (sv) Sett att framstella poperazinyl-kinoxalinforeningar.
SE410607B (sv) Sett att framstella pregnan-21-syraderivat
SE403478B (sv) Sett att framstella 2,2,6,6-tetrametyl-4-oxopiperidin
SE406327B (sv) Sett att framstella d-homo-1,4-pregnadien-3,20-dioner
SE416725B (sv) Forfarande for framstellning av p-nitrobensoesyra
SE403373B (sv) Sett att framstella aminosubstituerade tetracykliska foreningar
SE421129B (sv) Forfarande for framstellning av poly-n-alkyl-iminoalaner
SE401187B (sv) Sett att framstella deltaŸ4-3-ketosteroid-17-propiolakton
SE397190B (sv) Sett att framstella substituerade dibensocykloheptener
SE417317B (sv) Forfarande for framstellnig av tropa-alkaloider
SE403107B (sv) Sett att framstella 6-substituerade 3-etoxi-karbonyl hydrazino-pyridaziner
SE387111B (sv) Sett att framstella bensoylfenylguanidiner
SE404192B (sv) Sett att framstella 3 beta-cykloalkyloxi-16 alfa-cyanopregn-5-en-20-oner
SE396751B (sv) Sett att framstella s?72iv-benso-1,2,4-tiadiaziner
SE411342B (sv) Sett att framstella 4-acetamido-fenyl-3-acetoxibensoat
SE396219B (sv) Sett att framstella pyridyl-piperazinderivat
NO138406C (no) Fremgangsmaate for fremstilling av benzylaminer
SE420600B (sv) Forfarande for framstellning av 1,2,3,4-tetrahydroisokinoliner
SE384854B (sv) Sett att framstella 1-bensoyloxi-2-lagalylaminobensocykloalkanderivat
SE7513236L (sv) Sett att framstella furfurylidenhydrazinderivat

Legal Events

Date Code Title Description
SPCF Application for supplementary protection certificate filed

Free format text: 7401101

NUG Patent has lapsed

Ref document number: 7401101-6

Effective date: 19940210

Format of ref document f/p: F

SPCG Supplementary protection certificate granted

Free format text: 9490100, 910620, EXPIRES: 20020413